Durée du traitement anticoagulant oral dans la TVP des membres inférieurs

Hyers, 2001, Antithrombotic therapy for venous thromboembolic disease, Chest, 119, 176S, 10.1378/chest.119.1_suppl.176S Pinède, 2000, Optimal duration of anticoagulant therapy after an episode of venous thromboembolism, Blood Coagul Fibrinolysis, 11, 701, 10.1097/00001721-200012000-00002 Prandoni, 1996, The long term clinical course of acute deep venous thrombosis, Ann Intern Med, 125, 1, 10.7326/0003-4819-125-1-199607010-00001 Hansson, 2000, Recurrent venous thromboembolism after deep vein thrombosis, Arch Intern Med, 160, 769, 10.1001/archinte.160.6.769 1992, Optimum duration of anticoagulation for deep vein thrombosis and pulmonary embolism, Lancet, 340, 873, 10.1016/0140-6736(92)93285-U Schulman, 1995, A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism, New Engl J Med, 332, 1661, 10.1056/NEJM199506223322501 Levine, 1995, Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis, Thromb Haemost, 74, 606, 10.1055/s-0038-1649783 Kearon, 1999, A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism, New Engl J Med, 340, 901, 10.1056/NEJM199903253401201 Pinède, 2001, A comparison of three and six months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of six and twelve weeks after isolated calf deep vein thrombosis, Circulation, 103, 2453, 10.1161/01.CIR.103.20.2453 Agnelli, 2001, Three-months compared with one-year of oral anticoagulant treatment after a first idiopathic deep vein thrombosis: the Warfarin Optimal Duration Italian Trial – WODIT study, New Engl J Med, 345, 165, 10.1056/NEJM200107193450302 Palareti, 1996, Bleeding complications of oral anticoagulant treatment: an inception cohort prospective collaboration study (ISCOAT), Lancet, 348, 423, 10.1016/S0140-6736(96)01109-9 Van der Meer, 1993, Bleeding complications in oral anticoagulant therapy. An analysis of risk factors, Arch Intern Med, 153, 1557, 10.1001/archinte.1993.00410130073007 Landefeld, 1993, Anticoagulant related bleeding: clinical epidemiology, prediction, and prevention, Am J Med, 95, 315, 10.1016/0002-9343(93)90285-W Levine, 2001, Hemorrhagic complications of anticoagulant treatment, Chest, 119, 108S, 10.1378/chest.119.1_suppl.108S Beyth, 1998, Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin, Am J Med, 105, 91, 10.1016/S0002-9343(98)00198-3 White, 1999, Major bleeding after hospitalization for deep vein thrombosis, Am J Med, 107, 414, 10.1016/S0002-9343(99)00267-3 O'Sullivan, 1972, Duration of anticoagulant therapy in venous thromboembolism, Med J Aust, 2, 1104, 10.5694/j.1326-5377.1972.tb103752.x Holmgren, 1985, One-month versus six months therapy with oral anticoagulants after symptomatic deep vein thrombosis, Acta Med Scand, 218, 279, 10.1111/j.0954-6820.1985.tb06125.x Schulman, 1985, The duration of oral anticoagulation after deep vein thrombosis: a randomised study, Acta Med Scand, 217, 547, 10.1111/j.0954-6820.1985.tb03261.x Fennerty, 1987, A comparison of 3 and 6 weeks anticoagulation in the treatment of venous thromboembolism, Clin Lab Haematol, 9, 17, 10.1111/j.1365-2257.1987.tb01377.x Schulman, 1997, The duration of oral anticoagulant therapy after a second episode of venous thromboembolism, New Engl J Med, 336, 393, 10.1056/NEJM199702063360601 Hirsh, 1997, Duration of anticoagulant therapy after first episode of venous thrombosis in patients with inherited thrombophilia, Arch Intern Med, 157, 2174, 10.1001/archinte.1997.00440400024003 Kearon, 2000, Management of patients with hereditary hypercoagulable disorders, Annu Rev Med, 51, 169, 10.1146/annurev.med.51.1.169 Mannucci, 2000, Aspects of the clinical management of hereditary thrombophilia: a personal perspective, Haemostasis, 30, 11 Van den Belt, 1997, Recurrence of venous thromboembolism in patients with familial thrombophilia, Arch Intern Med, 157, 2227, 10.1001/archinte.1997.00440400077009 Van den Belt, 2000, Duration of oral anticoagulant treatment in patients with venous thromboembolism and a deficiency of antithrombin, protein C or protein S. A decision analysis, Thromb Haemost, 84, 740, 10.1055/s-0037-1614111 Seligsohn, 2001, Genetic susceptibility to venous thrombosis, New Engl J Med, 344, 1222, 10.1056/NEJM200104193441607 Eichinger, 1997, The risk of recurrent venous thromboembolism in patients with and without factor V Leiden, Thromb Haemost, 77, 624, 10.1055/s-0038-1656023 Simioni, 1997, The risk of recurrent venous thromboembolism in patients with an mutation in the gene for factor V, New Engl J Med, 336, 399, 10.1056/NEJM199702063360602 Sarasin, 1998, Decision analysis model of prolonged oral anticoagulant treatment in factor V Leiden carriers with first episode of deep vein thrombosis, British Med J, 316, 95, 10.1136/bmj.316.7125.95 Baglin, 1998, Risk of recurrent venous thromboembolism in patients with the factor V Leiden (FVR506Q) mutation: effect of warfarin and prediction by precipitating factors, British J Haematol, 100, 764, 10.1046/j.1365-2141.1998.00632.x Middeldorp, 2000, How to decide on the optimal duration of anticoagulant therapy in carriers of the factor V Leiden mutation, Thromb Haemost, 84, 740, 10.1055/s-0037-1614107 Eichinger, 1999, The risk of early recurrent venous thromboembolism after oral anticoagulant therapy in patients with G20210A transition in the prothrombin gene, Thromb Haemost, 81, 14, 10.1055/s-0037-1614409 Lindmarker, 1999, The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene. DURAC Trial Study Group, Thromb Haemost, 81, 684, 10.1055/s-0037-1614554 Ray, 1998, Meta-analysis of hyperhomocysteinemia as a risk factor for venous thromboembolic disease, Arch Intern Med, 158, 2101, 10.1001/archinte.158.19.2101 Eichinger, 1998, Hyperhomocysteinemia is a risk factor of recurrent venous thromboembolism, Thromb Haemost, 80, 566 De Stefano, 1999, The risk of recurrent deep vein thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation, New Engl J Med, 341, 801, 10.1056/NEJM199909093411104 Kyrle, 2000, High plasma levels of factor VIII and the risk of recurrent venous thromboembolism, New Engl J Med, 343, 457, 10.1056/NEJM200008173430702 Kraaijenhagen, 2000, High plasma concentration of factor VIIIc is a major risk factor of venous thromboembolism, Thromb Haemost, 83, 5, 10.1055/s-0037-1613747 Meijers, 2000, High level of coagulation factor XI as a risk factor for venous thrombosis, New Engl J Med, 342, 696, 10.1056/NEJM200003093421004 van Hylckama Vlieg, 2000, High levels of factor IX increase the risk of venous thrombosis, Blood, 95, 3678, 10.1182/blood.V95.12.3678 Schulman, 1998, Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy, Am J Med, 104, 332, 10.1016/S0002-9343(98)00060-6 Coccheri, 1999, Oral anticoagulant therapy: efficacy, safety and the low-dose controversy, Haemostasis, 29, 150 Klein, 1995, Equal effectiveness of very low intensity anticoagulation and standard low intensity anticoagulation : a pilot study, Southern Med J, 88, 1136, 10.1097/00007611-199511000-00010 Pinède, 2000, Comparison of long versus short duration of anticoagulant therapy after a first episode of venous thromboembolism. A meta-analysis of randomized controlled trials, J Intern Med, 247, 553, 10.1046/j.1365-2796.2000.00631.x Stewart, 1995, Practical methodology of meta-analyses (overview) using individual patient data, Statist Med, 14, 2057, 10.1002/sim.4780141902 Palaretti, 2002, Risk of venous thromboembolism recurrence: high negative predictive value of D-dimer performed after oral anticoagulation is stopped, Thromb Haemost, 87, 7, 10.1055/s-0037-1612936